News & Events

New leadership makes Floating Hospital’s research “nimbler and more focused”


Form follows function, and Floating Hospital’s newly reorganized research operation reflects the medical center’s commitment to making cutting-edge therapeutics as quickly and easily accessible as possible to young patients and the physicians who care for them.

Three respected physician-scientists whose talents and responsibilities span the spectrum from bench to bedside now share leadership of the research organization.

“Diana Bianchi, MD, Vice Chair for Research, is an internationally renowned geneticist who does bench-based research and serves as the global strategist for our research initiatives,” explains John Schreiber, MD, MPH, Floating’s Pediatrician-in-Chief and Chief Administrative Officer. Dr. Bianchi is also the founding Executive Director of the Mother and Infant Research Institute (MIRI).

“Jonathan Davis, MD, Vice Chair for Academic Affairs, is responsible for coordinating clinical and translational research, identifying which trials we can undertake, and integrating our research efforts with resident and fellow training to teach the next generation of pediatricians how to generate new knowledge while meeting regulatory and compliance issues,” Dr. Schreiber continues.

“And H. Cody Meissner, MD, who is Chief of the Division of Pediatric Infectious Diseases and Associate Director of our Clinical Microbiology Laboratory, is our physician leader on the front lines of clinical trials,” Dr. Schreiber says. “Together with dedicated clinical trials personnel, he has the responsibility of ensuring that our infrastructure keeps pace with our clinical trial needs.

“Our aim is to grow the Floating Hospital research portfolio in a way that’s different from how it’s done elsewhere in the city,” Dr. Schreiber notes. “We have three people at the helm whose expertise spans the bench to the bedside working together in an organized fashion. We believe it positions us as nimbler and more focused, and better able to serve referring physicians and their young patients.”

“We’re going to have available the most cutting-edge experimental therapeutics for physicians’ toughest cases, and we’re organized to deliver fast, responsive service,” he adds.